About us

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics. The company’s product portfolio comprises platform technologies for gene therapy viral vectors (AAV, Adeno, Lenti) and complex recombinant proteins.

CEVEC has developed the first truly stable AAV Producer Cell which has all components necessary for AAV production stably integrated into the genome of the cells. The helper virus-free platform based on human suspension cells delivers a consistent quality of AAV vectors over time due to the elimination of any transfection step.

CEVEC’s CAP® Technology based on human suspension cells is the ideal production platform for RCA-free adeno viral vectors, lentiviral vectors, viral vaccines and oncolytic viruses.

With CAP®-Go CEVEC serves the increasing need for recombinant production of complex and highly glycosylated molecules, including laminins, coagulation factors and other plasma proteins.

Products and services

CEVEC’s first and only true AAV Producer Cell Lines comprise:

• Licenses to single producer cell lines or technology licenses
• Development of tailor-made AAV Producer Cell Lines
• Process Development, including media, USP and DSP
• Scale-up to manufacturing scale
• GMP Master Cell Bank services
• Providing small-scale AAV material for pre-clinical research

CEVEC’s CAP® Technology comprises:

• Licenses to CAP® Cell Lines
• CAP® Cell Lines for RCA-free Adeno viral vector production
• Provision of research cell banks
• Provision of GMP MCB and GMP WCB


CEVEC’s CAP® Go Technology comprises:

• Licenses to CAP® Go cell lines
• Portfolio of glyco-optimized CAP® Go cell lines
• Development of tailor-made cell lines for expression of recombinant proteins with optimized pharmacokinetic profiles
• Upstream Process Development and Scale Up to manufacturing scale
• Downstream Process Development

Stable AAV Producer Cell Lines

Stable AAV Producer Cell Lines

CEVEC Pharmaceuticals

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics. The company’s product portfolio comprises platform technologies for gene therapy viral vectors (AAV, Adeno, Lenti) and complex recombinant proteins.

CAP-Go

CAP-Go enables the production of proteins “beyond antibodies”.

Address
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Str. 60-62
51105 Cologne
Germany

Phone: +49 221 46020800
Internet: www.cevec.com
E-mail: Send message

Contact person

Petra, Nitschke
Business Development Manager
Phone: +49 221 46020800
E-mail: Send message

Click here if you notice an image that violates copyright or privacy rights.

Get in contact
OK

We use cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection